SOPHiA GENETICS (NASDAQ:SOPH) Coverage Initiated by Analysts at Guggenheim

Stock analysts at Guggenheim began coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a note issued to investors on Thursday, Benzinga reports. The brokerage set a “buy” rating and a $6.00 price target on the stock. Guggenheim’s price target points to a potential upside of 34.53% from the company’s previous close.

SOPH has been the topic of a number of other research reports. BTIG Research upped their price objective on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Wednesday, March 6th.

SOPHiA GENETICS Trading Down 0.4 %

SOPH opened at $4.46 on Thursday. The stock has a market capitalization of $291.59 million, a P/E ratio of -3.98 and a beta of 1.09. The firm’s fifty day simple moving average is $4.86 and its 200 day simple moving average is $4.82. SOPHiA GENETICS has a 12 month low of $2.13 and a 12 month high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. SOPHiA GENETICS had a negative return on equity of 47.56% and a negative net margin of 113.71%. The business had revenue of $15.78 million during the quarter, compared to the consensus estimate of $16.80 million. On average, equities research analysts predict that SOPHiA GENETICS will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of SOPH. Federated Hermes Inc. boosted its holdings in shares of SOPHiA GENETICS by 100.0% during the 3rd quarter. Federated Hermes Inc. now owns 160,000 shares of the company’s stock worth $408,000 after buying an additional 80,000 shares during the period. Banque Pictet & Cie SA boosted its holdings in shares of SOPHiA GENETICS by 2.3% during the third quarter. Banque Pictet & Cie SA now owns 2,237,340 shares of the company’s stock worth $5,705,000 after acquiring an additional 50,000 shares during the period. Legato Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $235,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of SOPHiA GENETICS by 90.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,834 shares of the company’s stock worth $65,000 after purchasing an additional 6,552 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in SOPHiA GENETICS by 2.6% during the 4th quarter. Principal Financial Group Inc. now owns 995,500 shares of the company’s stock worth $4,689,000 after purchasing an additional 24,837 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.